Hear from a multidisciplinary panel of leading Australian healthcare professionals as they discuss the importance of biosimilar medicines and tips for supporting patient education and confidence
This activity will take approximately one hour to complete and includes reflection questions.
Upon completion of this activity, participants will be able to:
| 1 |
Outline the clinical development and regulatory processes required prior to approval of biosimilar medicines |
| 2 |
Explain to patients what a biosimilar medicine is, why it is different to a generic medicine, and their therapeutic equivalence to the reference biological product |
| 3 |
Explain how biosimilar medicines contribute to the sustainability of the Australian healthcare system |
This activity has been approved for two (2) CPD Activity points in the RACGP CPD 2020-2022 triennium.
Accreditation number: 231585.